

Press Release


Cipla announces Q2 FY1516 Unaudited Consolidated Financial Results


Mumbai, India, 5th Nov 2015: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended Sep 30, 2015 (Q2).

Key Financial & Performance Highlights Q2 FY1516 vis-a-vis Q2 FY1415:

(Current year figures include the relevant results of Cipla's subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Income from operations grew by 24.8% to Rs. 3,452 cr, up from Rs. 2,767 cr
- EBITDA grew by 41.4% to Rs. 789 cr, up from Rs. 558 cr
- Profit after tax grew by 44.4% to Rs. 431 cr, up from Rs. 299 cr





Profit & Loss Highlights:

- Material cost is at 35.2% of income from operations in Q2 FY1516 as compared to 36.7% in Q2 FY1415
- EBIDTA as % of income from operations increased to 22.9% in Q2 FY1516 from 20.2% in Q2 FY1415
- Profit after tax grew by 44.4% to Rs. 431 cr, up from Rs. 299 cr in Q2 FY1415
- The results for the current period includes a one-off revenue from the USA market

Performance Review:

Domestic business:

• Domestic sales grew by 0.9% to Rs. 1,262 cr during Q2 FY1516 from Rs. 1,251 cr during Q2 FY1415

International business:

- Exports of formulations increased by 51.3% to Rs. 1,874 cr during Q2 FY1516, from Rs. 1,239 cr during Q2 FY1415.
- Exports of APIs increased by 61% to Rs. 226 cr during Q2 FY1516, from Rs. 140 cr during Q2 FY1415.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla's portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla's turnover in 2014/15 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contacts:

Investor Relations Anant Atal Contact No.: 022 – 24826450 E-Mail: <u>anant.atal@cipla.com</u> **Corporate Communications** Pallavi Golar Contact No.: +91 9833641788 E Mail: <u>pallavi.golar@cipla.com</u>